Saturday 17 October 2026
Export ORGS’s income statement to Excel — free account
Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.
0.06
0.06
Infinity
Follow ORGS
| Nov '17 | Dec '17 | Nov '18 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 5 | 3 | 3 | 1 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 5.01 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.40 | 6.31 | 5.60 | 3.05 | 19.01 | 12.54 | 1.97 | 1.37 | 26.93 | 7.69 |
Altman Z-Score |
(1.50) | 11.85 | (0.31) | (0.74) | (1.11) | (2.73) | (0.64) | (0.96) | (29.89) | (352.42) |
P/FCF ratio |
20.69 | 24.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(6.51) | (7.90) | (2.22) | (2.85) | (2.13) | (6.92) | (4.63) | (2.41) | (70.52) | (868.26) |
Beneish M-Score |
(4.52) | — | (0.54) | — | — | — | — | (1.20) | — | — |
P/Operating CF |
(27.90) | (32.61) | (15.49) | (14.60) | (27.40) | (2.12) | (28.37) | (4.57) | (28.43) | (3.79) |
P/B ratio |
3.28 | 3.83 | 3.01 | 2.34 | 12.20 | 1.82 | 1.81 | 1.69 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.10 | 3.80 | 4.40 | 0.00 | 0.00 |
EV/Sales |
5.90 | 6.81 | 4.81 | 2.54 | 22.19 | 8.07 | 2.10 | 1.69 | 66.20 | 23.15 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
16.44 | 18.98 | (5.25) | (3.11) | (6.54) | (0.79) | (2.78) | (2.44) | (2.36) | (1.40) |
EV/FCF |
22.60 | 26.10 | (3.96) | (2.28) | (3.42) | (0.78) | (2.15) | (1.64) | (2.07) | (1.38) |
Quick Ratio |
0.34 | 0.34 | 1.61 | 1.47 | 0.06 | 3.00 | 1.39 | 2.67 | 0.12 | 0.03 |
Current Ratio |
0.43 | 0.43 | 1.77 | 1.64 | 1.85 | 3.08 | 1.68 | 2.91 | 0.25 | 0.03 |
Net Debt/EBITDA |
(0.50) | (0.56) | 1.06 | 0.75 | (0.68) | 0.36 | (0.32) | (1.42) | (0.40) | (0.42) |
Debt/Assets |
19.58% | 19.29% | 4.94% | 6.13% | 14.00% | 14.65% | 18.01% | 19.73% | 153.18% | 1,235.53% |
Debt/Equity |
0.55 | 0.54 | 0.13 | 0.17 | 2.13 | 0.22 | 0.28 | 0.62 | (1.06) | (0.44) |
Asset Turnover |
0.28 | 0.25 | 0.32 | 0.27 | 0.05 | 0.09 | 0.52 | 0.48 | 0.01 | 0.13 |
Operating CF/Net income |
0.31 | 0.31 | 0.86 | 0.76 | 0.55 | (70.31) | 1.49 | 1.67 | 0.27 | 0.35 |
Capex/Depreciation |
(0.38) | 0.00 | (2.12) | (2.11) | (3.17) | (1.06) | (4.22) | (6.15) | (1.34) | (0.13) |
Interest Coverage |
(4.59) | — | (4.70) | (5.37) | (26.07) | (90.27) | (13.00) | (5.13) | (21.46) | (8.82) |
| (92.92%) | (87.57%) | (85.53%) | (79.78%) | (146.95%) | 3.78% | (39.52%) | (43.98%) | (1,368.97%) | 164.62% | |
| (33.72%) | (31.02%) | (31.72%) | (29.60%) | (29.00%) | 1.30% | (26.25%) | (19.75%) | (104.97%) | (605.73%) | |
ROIC |
(38.12%) | 0.00% | (57.52%) | (64.80%) | (74.42%) | (322.83%) | (24.17%) | (15.55%) | 0.00% | 0.00% |
Return on Tangible Assets |
273.91% | 273.91% | (73.01%) | (94.62%) | (63.11%) | 3.01% | (87.36%) | (27.96%) | 509.96% | 188.28% |
Average Days of Receivables |
79.95 | 79.95 | 218.98 | 182.74 | 190.50 | 155.22 | 158.47 | 366.60 | 376.02 | 14.11 |
Research and Development Expense of Revenue |
24.56% | 23.47% | 34.65% | 38.50% | 346.06% | 1,089.69% | 100.75% | 60.88% | 2,004.34% | 929.66% |
Selling, General and Administrative Expense of Revenue |
91.08% | 91.08% | 87.39% | 89.17% | 293.69% | 247.95% | 41.43% | 43.27% | 6,629.06% | 1,432.08% |
Intangible Assets out of Total Assets |
0.65 | 0.65 | 0.42 | 0.43 | 0.09 | 0.28 | 0.34 | 0.20 | 0.59 | 0.00 |
Share Based Compensation of Revenue |
33.34% | 0.00% | 23.39% | 24.86% | 146.14% | 260.00% | 4.92% | 2.73% | 87.36% | 308.60% |
Graham Net Nets |
(0.40) | (0.34) | (0.19) | (0.30) | (0.11) | 0.26 | 0.07 | (0.32) | (2.20) | (4.79) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 28.28 | 111.89 | 0.00 | 0.00 | 45.95 | 48.05 |
Earnings Yield |
(35.31%) | (30.21%) | (22.92%) | (35.17%) | 19.96% | 49.99% | (25.69%) | (24.74%) | (263.70%) | (608.99%) |
Free Cash Flow Yield |
4.83% | 4.14% | (21.71%) | (36.51%) | (34.09%) | (82.93%) | (49.68%) | (75.41%) | (118.65%) | (217.87%) |
Revenue per Share |
10.42 | 1.04 | 13.95 | 15.33 | 2.45 | 3.59 | 14.63 | 14.35 | 0.18 | 0.25 |
Operating CF per Share |
(3.96) | (0.40) | (11.73) | (12.53) | (8.31) | (36.61) | (11.07) | (9.93) | (5.11) | (4.06) |
Capex per Share |
(1.01) | 0.00 | (4.15) | (4.55) | (7.57) | (0.71) | (3.24) | (4.85) | (0.72) | (0.06) |
Free Cash Flow per Share |
(4.97) | (0.40) | (15.88) | (17.09) | (15.89) | (37.32) | (14.31) | (14.78) | (5.84) | (4.12) |
Cash per Share |
3.64 | 0.36 | 12.30 | 11.22 | 0.36 | 21.37 | 2.46 | 2.54 | 0.51 | 0.16 |
Shareholders Equity per Share |
14.59 | 1.46 | 21.42 | 20.00 | 3.82 | 24.73 | 15.91 | 11.58 | (7.23) | (8.91) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.59 | 1.46 | 21.42 | 20.00 | 3.82 | 24.73 | 15.91 | 11.58 | (7.23) | (8.91) |
Free Cash Flow |
(4.81) | (3.83) | (21.24) | (22.85) | (25.27) | (79.56) | (34.73) | (37.09) | (16.93) | (17.34) |
Working Capital |
(9.62) | (9.62) | 13.15 | 10.90 | 35.91 | 33.79 | 10.39 | 30.41 | (12.33) | (26.16) |
Capital Expenditures |
(0.97) | (0.97) | (5.56) | (6.09) | (12.05) | (1.52) | (7.87) | (12.17) | (2.10) | (0.26) |
Net Current Asset Value |
(18.45) | (14.85) | (16.50) | (19.07) | (8.07) | 25.12 | 4.55 | (15.54) | (31.46) | (38.12) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.00 | 0.30 | 0.30 | 3.09 | 0.20 | 0.22 | 0.34 | 3.95 | 0.25 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.51 | 0.51 | 0.22 | 0.23 | 1.65 | 0.47 | 0.18 | 0.09 | 1.06 | 3.61 |
Cash ROIC |
(18.89%) | (15.13%) | (43.49%) | (49.37%) | (128.92%) | (72.54%) | (62.71%) | (69.49%) | (607.57%) | 86.03% |
Accounts Receivable Turnover |
4.64 | 4.57 | 2.78 | 1.91 | 0.63 | 2.89 | 3.80 | 1.40 | 0.03 | 3.53 |
Accounts Payable Turnover |
1.61 | 2.18 | 2.80 | 2.87 | 2.77 | 11.83 | 5.28 | 1.06 | 1.14 | 0.20 |
Inventory Turnover |
12.10 | 11.79 | 8.80 | 7.09 | 15.61 | 523.28 | 241.87 | 43.13 | 81.23 | 0.00 |
Average Days of Payables |
209.87 | 167.13 | 128.28 | 138.88 | 144.53 | 37.59 | 52.17 | 314.94 | 384.20 | 2,484.39 |
Days of Inventory on Hand |
38.88 | 30.96 | 58.54 | 50.30 | 3.54 | 0.80 | 1.18 | 8.53 | 1.98 | 0.00 |
Average Receivables |
2.17 | 2.21 | 6.70 | 10.73 | 6.15 | 2.64 | 9.33 | 25.80 | 18.36 | 0.29 |
Average Payables |
4.23 | 3.91 | 3.86 | 4.19 | 5.07 | 7.10 | 6.94 | 4.83 | 5.51 | 9.85 |
Average Inventory |
0.56 | 0.73 | 1.23 | 1.70 | 0.90 | 0.16 | 0.15 | 0.12 | 0.08 | — |
Average Assets |
36.68 | 39.87 | 57.66 | 74.66 | 83.19 | 85.09 | 68.76 | 75.38 | 52.74 | 7.95 |
Average Common Equity |
13.31 | 14.12 | 21.39 | 27.70 | 16.41 | 29.40 | 45.68 | 33.85 | 4.04 | (29.26) |
Columns are period end dates